Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RESP-X
- Development stage
- Unknown
- Lead developer
- Infex Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
RESP-X is a first-in-class anti-virulence monoclonal antibody developed by Infex Therapeutics for the treatment of chronic *Pseudomonas aeruginosa* infections in patients with non-cystic fibrosis bronchiectasis (NCFB). Unlike traditional antibiotics that attempt to kill bacteria, RESP-X targets the virulence factors of the pathogen, specifically the PcrV protein which is a key component of the *P. aeruginosa* Type III Secretion System (T3SS). By neutralizing this system, the drug prevents the bacteria from injecting toxins into host cells and evading the immune response. The primary therapeutic goal is to reduce the frequency and severity of debilitating respiratory exacerbations in patients colonized with chronic *P. aeruginosa*. It is currently in Phase II clinical development.
- Brand names
- RESP-X
02
Targets
PcrV (Type III secretion protein PcrV)T3SS (Pseudomonas aeruginosa Type III secretion system)
Beyond the preview
Go deeper on RESP-X.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RESP-X.